Neuroendocrine tumour

What is Neuroendocrine tumour?

Neuroendocrine tumours (NETs) are tumours composed of neuroendocrine cells, which are cells that produce and secrete regulatory hormones and are present throughout the nervous and endocrine/hormonal systems. As neuroendocrine cells are distributed widely throughout the body, tumours of these cells can occur at many sites.Examples of neuroendocrine tumours are:

Carcinoid tumour

Pancreatic endocrine tumour

Gastrinoma

Insulinoma

Glucagonoma

VIPoma (vasoactive intestinal polypeptide tumour)

Paraganglioma

Pheochromocytoma

Medullary thyroid carcinoma

Poorly differentiated small cell neuroendocrine carcinoma

Statistics on Neuroendocrine tumour?

Neuroendocrine tumours are generally rare. The occurance rate is about 0.1-1 per million per year. Glucagonomas are among the rarest of the NETs.

Risk Factors for Neuroendocrine tumour

The exact cause is unknown.Neuroendocrine tumours can arise spontaneously in a random fashion or as a result of genetic changes.Neuroendocrine tumors may associated with the following conditions inherited genetically:

multiple endocrine neoplasia (MEN) types 1 and 2

von Hippel-Lindau (VHL) disease

von Recklinghausens neurofibromatosis (NF)

tuberculous sclerosis (TSC)

Progression of Neuroendocrine tumour

Neuroendocrine tumours are rare cancers that are often misdiagnosed. Because symptoms vary widely depending on where the cancer happens, a diagnosis is frequently made only after the cancer has spread/metastasised to other parts of the body. Most neuroendocrine tumours are malignant, except insulinoma. They commonly spread to the lymph nodes and the liver. Some other uncommon sites of distant spread include the bone, lung, brain and other organs. Despite the ability to metastasise/spread, most malignant neuroendocrine tumours are slow-growing. An exception is the poorly differentiated small cell neuroendocrine carcinoma, which is highly malignant, fast-growing, but fortunately rare. Depending on whether the neuroendocrine tumours lead to a specific clinical syndrome, they are termed "functionally active" and "functionally inactive". Functionally active NETs produce clinical symptoms because of excessive hormone release from the tumour cell. Examples of NETs that may be functionally active are insulinoma, gastrinoma, VIPoma, glucogonoma (producing the glucagonoma syndrome), carcinoid tumour (producing the carcinoid syndrome).

How is Neuroendocrine tumour Diagnosed?

The usual basic tests will be done, including those to look at the blood and other blood components. Other general tests will determine the function of the liver and kidney.

Prognosis of Neuroendocrine tumour

Prognosis is different for different types of neuroendocrine tumour. For example:

For insulinoma, long term survival following surgical removal in this patient population exceeds 90%.

For carcinoid tumour, the survival rate at 5 years following diagnosis (5-year survival rate) for all carcinoid tumours, regardless of the site of tumour, is 67%Grading of the tumour based on findings under the microscope is difficult for neuroendocrine tumours. Recent research showed that in malignant neuroendocrine tumours, a few factors confer poor survival:

a high expression of a protein called the Ki 67 protein

the presence of aneuploidy (abnormal amount of genetic material)

How is Neuroendocrine tumour Treated?

The aim of treatment is to control tumour growth and the symptoms caused by hormone release. Surgery:

Surgical removal is always attempted for benign tumours.

In more extensive diseases, surgery is also considered to reduce the bulk of tumour.Medical treatment:Somatostatin analog:

drug that mimics the hormone somatostatin, drug of first choice to control symptoms

Octreotide and lanreotide is efficient in the control of watery diarrhoea in VIPoma, skin reddening in glucanogoma syndrome, and flushing & diarrhoea in carcinoid syndrome.

Somatostain analog also has effect on tumour growth control. Alfa-interferon:

Since its use in 1982, alfa-interferon has been shown to be comparable to long-acting somatostain analog in the control of hormone release and tumour growth.Proton-pump inhibitors:

At higher doses, this group of drugs can control excessive secretion of acid from the stomach in the case of gastrinoma. Chemotherapy:

Neuroendocrine tumours in the pancreas respond well to chemotherapy.

Tumours e.g. carcinoid tumour generally do not show good response to chemotherapy.Other:Other treatment options include nutritional modification, radiofrequency ablation (the use of electrodes to heat and destroy abnormal tissue), cryoablation (the use of extreme cold to freeze abnormal tissue), chemoembolisation (blocking the blood supply to the tumour).

Neuroendocrine tumour References

[1] Arnold R. Diagnosis and management of neuroendocrine tumors [online]. 2001 [cited 2005 Dec 23]. Available from: URL: http://www.medscape.com/viewarticle/420088?src=search Proceedings of the 8th United European Gastroenterology Week; 2000 Nov 25-30; Brussels, Belgium.[2] Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues. Digestion. 2000;62 (suppl 1):84-91.[3] Bishop AE, Power RF, Polak JM. Markers of neuroendocrine differentiation. Pathol Res Pract. 1988;183:119-128.[4] Calender A. Molecular genetics of neuroendocrine tumors. Digestion. 2000; 62(suppl 1): 3-18.[5] Di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer. 1996;77:402-408.[6] Kasper DL et al, editors. Harrison's principles of internal medicine. 16th ed. New York; London: McGraw-Hill; 2005. [7] Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003 Feb 15;97(4):934-59.[8] Moertel CG, Lefkopoulos M, Lipsitz M. Streptozocin-doxurubicin, streptozocin-fluorouracil of chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519-523.[9] Neuroendocrine tumors [online]. 2003 [cited 2005 Dec 23]. Availble from: URL: http://research.dfci.harvard.edu/neuroendocrine/localized/index.php[10] Oberg K. Interferon in the management of neuroendocrine GEP-tumors: A review. Digestion 2000; 62(suppl1): 92-7.[11] Rindi G, Azzoni C, La Rossa S, et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: Prognostic evaluation by pathological analysis. Gastroenterology. 1999;116:532-542.[12] Saltz L, Trochanowsky G, Buckley M, et al. Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumours. Cancer. 1993;72:244-248.[13] Winkler H, Fischer-Colbrie B. The chromogranins A and B, the first years and future perspectives. Neuroscience. 1992;49:497-528.